That’s the message Biogen chief executive Chris Viehbacher conveyed to Governor Maura Healey, during a Q&A session following her speech on Thursday at an Associated Industries of Massachusetts ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Anheuser-Busch InBev is making a play in the US energy-drinks category through a tie-up with sports-nutrition and supplements group 1st Phorm. The companies will work together to launch an energy ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

Known for pushing boundaries with its artistic designs and creative flavors for its line of 70-plus doughnuts, Pinkbox Doughnuts is now debuting its own caffeinated energy drink that packs a punch and ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Anheuser-Busch InBev is making a play in the US energy-drinks category through a tie-up with sports-nutrition and supplements group 1st Phorm. The companies will work together to launch an ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Biogen ( (BIIB ...

Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue, with ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...